DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Schmid P, Cortés J, Dent R. et al.
KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs. placebo (pbo) + chemo as neoadjuvant treatment, followed by pembro vs. pbo as adjuvant treatment for early triple-negative breast cancer (TNBC).
Ann Oncol 2019;
30 (Suppl. 05) v851-v934
doi:10.1093/annonc/mdz394
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.